Multiple myeloma · 4 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ITd Variant #01 | — | R 41 519 | 28d | 20.0 mo | — | 22 | R 913 411 PFS proxy | 1 |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | 33.6 mo | — | 30 | R 256 183 PFS proxy | 3 |
Melphalan monotherapy Variant #01 | — | R 71 | 42d | 50.0 mo | — | 37 | R 2 636 PFS proxy | 4 |
Observation Partial | — | — | — | 13.0 mo | — | — | — | 1 |
4 of 4 regimens shown